{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"60","value":"33.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Overall survival will be calculated from the time of surgery to the time of death for any cause and will be censored at the date of last follow up visit for patients who are still alive or lost to follow up.","dispersionType":"Full Range","groups":[{"description":"HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, were administered into the inflow line of the perfusion circuit once target temperature was reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, was administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period had elapsed, the perfusate was drained into the waste reservoir. The peritoneal cavity was rinsed/washed-out.\n\nHIPEC\n\nMitomycin C","id":"OG000","title":"HIPEC + Mitomycin C"}],"paramType":"MEDIAN","populationDescription":"For OS, 12/51 patients were not evaluable due to either never having completed surgery, not receiving HIPEC, or having no evidence of cancer at time of surgery. As such, 39 patients were evaluable for OS. 2 patients died within 30 days of surgery and, as such, the full range of dates was 0 months to time of last follow up prior to study termination (i.e., 60 months)","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}